{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:32:40Z","timestamp":1790778760570,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Research Foundation\u2014Flanders"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A paired serum sample and colonic mucosal biopsy was collected from 40 UC patients [20 endoscopic responders, 20 non-responders] at week 14 of vedolizumab treatment. Vedolizumab, soluble [s]-mucosal addressin cell adhesion molecule-1 [MAdCAM-1], s-vascular cell adhesion molecule-1 [VCAM-1] and s-intercellular adhesion molecule-1 [ICAM-1] were measured in serum and\/or tissue. Endoscopic response was defined as Mayo endoscopic sub-score \u22641.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A significant positive correlation was observed between vedolizumab serum and colonic tissue concentrations [\u03c1 = 0.84, p &amp;lt; 0.0001], regardless of the macroscopic inflammatory state of the tissue. Vedolizumab tissue concentrations were lower in non-responders than in responders [0.07 vs 0.11 \u00b5g\/mg, p = 0.04]. In the subgroup of patients with adequate vedolizumab serum concentrations [&amp;gt;14.6 \u00b5g\/mL], tissue vedolizumab was not significantly different between responders and non-responders [0.15 vs 0.13 \u00b5g\/mg; p = 0.92]. Serum sMAdCAM-1 concentrations, but not serum sICAM-1 or sVCAM-1 concentrations, were significantly higher in responders than in non-responders with adequate vedolizumab serum concentrations [1.04 vs 0.83 ng\/mL, p = 0.03].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Vedolizumab concentrations in colonic mucosal tissue of UC patients reflect the concentration in serum regardless of the macroscopic inflammatory state of the tissue. Our data show that insufficient tissue exposure does not explain non-response in UC patients with adequate serum vedolizumab concentrations.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa239","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T21:37:01Z","timestamp":1605735421000},"page":"988-993","source":"Crossref","is-referenced-by-count":13,"title":["Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0026-4498","authenticated-orcid":false,"given":"Nathalie","family":"Van den Berghe","sequence":"first","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Gils","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Sabino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-9105","authenticated-orcid":false,"given":"Paul","family":"Declerck","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-9846","authenticated-orcid":false,"given":"Debby","family":"Thomas","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"2021062213004312000_CIT0001","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: pathogenesis of Crohn\u2019s disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"2021062213004312000_CIT0002","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2021062213004312000_CIT0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2021062213004312000_CIT0004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2021062213004312000_CIT0005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2021062213004312000_CIT0006","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021062213004312000_CIT0007","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-\u03b1 levels in inflammatory bowel disease","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2021062213004312000_CIT0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/flgastro-2012-100241","article-title":"Value of drug level testing and antibody assays in optimising biological therapy","volume":"4","author":"Vermeire","year":"2013","journal-title":"Frontline Gastroenterol"},{"key":"2021062213004312000_CIT0009","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021062213004312000_CIT0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2021062213004312000_CIT0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MEG.0000000000001356","article-title":"Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance","volume":"31","author":"Liefferinckx","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021062213004312000_CIT0012","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ecco-jcc\/jjz151","article-title":"Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-tumour necrosis factor [TNF] na\u00efve and anti-TNF exposed IBD patients","volume":"14","author":"Verstockt","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2021062213004312000_CIT0013","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"2021062213004312000_CIT0014","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/gutjnl-2015-310022","article-title":"Differential effects of \u03b14\u03b27 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo","volume":"65","author":"Fischer","year":"2016","journal-title":"Gut"},{"key":"2021062213004312000_CIT0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2019","journal-title":"Gut"},{"key":"2021062213004312000_CIT0016","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mi.2015.82","article-title":"\u03b27-integrin exacerbates experimental DSS-induced colitis in mice by directing inflammatory monocytes into the colon","volume":"9","author":"Schippers","year":"2016","journal-title":"Mucosal Immunol"},{"key":"2021062213004312000_CIT0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/gutjnl-2018-316777","article-title":"Mechanism of action of vedolizumab: do we really understand it?","volume":"68","author":"Rogler","year":"2019","journal-title":"Gut"},{"key":"2021062213004312000_CIT0018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2249.2002.01984.x","article-title":"Increased expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and lymphocyte recruitment in murine gastritis induced by Helicobacter pylori","volume":"130","author":"Hatanaka","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"2021062213004312000_CIT0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2249.2001.01690.x","article-title":"Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats","volume":"126","author":"Hokari","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"2021062213004312000_CIT0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.0818-9641.2004.01247.x","article-title":"Bioassay detects soluble MAdCAM-1 in body fluids","volume":"82","author":"Leung","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"2021062213004312000_CIT0021","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0000000000000618","article-title":"Increased cell adhesion molecules, PECAM-1, ICAM-3, or VCAM-1, predict increased risk for flare in patients with quiescent inflammatory bowel disease","volume":"51","author":"Gu","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2021062213004312000_CIT0022","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/gast.2001.29568","article-title":"Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1\/Yit adoptive transfer model of Crohn\u2019s disease in mice","volume":"121","author":"Burns","year":"2001","journal-title":"Gastroenterology"},{"key":"2021062213004312000_CIT0023","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00042737-199511000-00005","article-title":"Circulating soluble adhesion molecules in inflammatory bowel disease","volume":"7","author":"Patel","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021062213004312000_CIT0024","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12876-020-01253-8","article-title":"Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study","volume":"20","author":"Allner","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2021062213004312000_CIT0025","first-page":"1089","article-title":"Soluble mucosal addressin cell adhesion molecule 1 and retinoic acid are potential tools for therapeutic drug monitoring in patients with inflammatory bowel disease treated with vedolizumab: a proof of concept study","volume":"12","author":"Paul","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2021062213004312000_CIT0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cpt.6","article-title":"Targeting leukocyte trafficking for the treatment of inflammatory bowel disease","volume":"97","author":"Arseneau","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2021062213004312000_CIT0027","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MIB.0000000000001029","article-title":"The \u03b14\u03b21 homing pathway is essential for ileal homing of Crohn\u2019s disease effector T cells in vivo","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa239\/34558945\/jjaa239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/988\/38756724\/jjaa239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/988\/38756724\/jjaa239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T16:39:53Z","timestamp":1723912793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/6\/988\/6007493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa239","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,11,27]]}}}